Orilissa Patient Assistance Program
Orilissa is a tablet prescribed for adult women to manage the moderate to severe pain that comes with endometriosis. Its active ingredient, elagolix, lowers the body’s production of certain hormones that feed endometriosis, easing the pelvic pain, painful periods, and pain during intercourse the condition can bring.
Endometriosis pain can shape entire days, pulling you away from work, plans, and the life you want to live. Orilissa can bring real relief, but that relief holds only when you’re able to keep taking it.
When the cost outpaces what your insurance covers, or you do not have insurance, a Patient Assistance Program (PAP) may open a door if you qualify.
How Prescription Details Affect Orilissa Assistance Eligibility
About the Orilissa Patient Assistance Program
These programs are something drugmakers put in place so their medicines can reach patients who otherwise couldn’t afford them. Orilissa’s is meant for adult women living with endometriosis whose coverage doesn’t stretch far enough to make it affordable.
Two things start the process: a prescription from the gynecologist or physician treating your endometriosis, and paperwork reflecting your household income over the past year.
With those in our hands, we take over from there. The manufacturer’s required clinical information is requested from your doctor, your income documents are arranged to fit the program’s format, and everything is filed together as one application. We follow its progress while it’s reviewed, and an approval sends your Orilissa to you for continued treatment. Meeting the requirements still doesn’t lock in acceptance, since the manufacturer decides each application on its own merits.
How Orilissa Works
Endometriosis happens when tissue much like the lining of the uterus grows outside it, and that tissue responds to estrogen by inflaming and causing pain. The more estrogen circulating, the more that tissue tends to flare.
Elagolix works by turning down estrogen production.
It blocks a receptor in the brain that signals the ovaries to make estrogen, which lowers the hormone levels feeding the endometriosis tissue. With less estrogen driving it, the inflammation and pain tend to ease. Your doctor can prescribe a lower or higher dose depending on how severe your symptoms are and which ones trouble you most.
Orilissa is prescribed at 150 mg once daily for up to 24 months, or 200 mg twice daily for up to six months.
Side Effects and Safety Information
Because Orilissa lowers estrogen, many of its effects mirror what happens when estrogen drops. Hot flashes and night sweats are the most common, along with headaches, trouble sleeping, and changes in mood.
Lower estrogen also thins bone over time, so Orilissa can reduce bone density, which is part of why treatment is capped at a limited duration and why your doctor may weigh your bone health before and during use. It is contraindicated in patients with known osteoporosis.
The medication can affect mood more seriously in some people, including new or worsening depression and thoughts of self-harm, so any notable shift in how you feel deserves prompt attention. It may also change your menstrual bleeding, which can make it harder to notice a pregnancy, so reliable non-hormonal birth control matters during and for 28 days following treatment. Because Orilissa isn’t safe in pregnancy, tell your doctor right away if you think you might be pregnant.
Orilissa is also contraindicated in patients with severe liver impairment.
Step 1 – Submit Application
Provide basic prescription and household information to begin the application process.
Step 2 – Application Review
Information is reviewed and submitted to appropriate Patient Assistance Programs.
Step 3 – Program Decision
Final eligibility decisions are made by each program. Additional steps or renewals may be required.
PHN will contact you within 24 hours to discuss your situation and help identify appropriate next steps for the application process.
How it applies / Eligibility
To qualify, you’ll need to meet all of the following:
- Single patients earning less than $40,000 per year
- Couples making under $60,000 combined yearly
- Households with three or more people bringing in below $100,000 annually
- Active Orilissa prescription from your healthcare provider
- Proof of U.S. citizenship or legal residency
- Limited or inadequate prescription drug coverage for Orilissa
Income tends to carry the most weight, though it’s read alongside the rest of your situation, and every application is decided on its own.
Frequently asked questions (FAQ`s)
The program sends the reason in writing. Most often it’s income over the cutoff, insurance the manufacturer treats as enough, or an application with something missing. When your income changes or the missing document turns up, you’re free to apply again.
Approval holds for a year, then calls for renewal. Before the deadline, you turn in current income records and your doctor’s confirmation that Orilissa is still appropriate. Miss that window and your participation lapses.
Proof of citizenship or legal residency, a full year of household income records, a current Orilissa prescription from a licensed provider, and a rundown of the drug coverage you hold.
We handle enrollment from the first step to the last, confirming you meet the standards, pulling your paperwork together, coordinating with your care team, and delivering a complete application to the manufacturer.
No generic form of finerenone is available right now. Those approved receive brand-name Kerendia.
It depends on the manufacturer’s workload and how many reviewers are free at the time. We stay in touch and pass along updates as they reach us.
They can. A manufacturer may shift an income limit, redefine what counts as adequate coverage, or adjust another term as its goals change. We keep watch on the programs and reach out when a change affects where you stand.
Associated Conditions & Medications
